Healthcare / BiotechnologyTaipei Exchange
$71.70
+0.10 (+0.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $408.9M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
12.3x
↓EV/EBITDA
4.9x
↓ROE
10.1%
↑Gross Margin
34.6%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.6%
FCF CAGR
—
FCF margin
38.5%
FCF / Net income
1.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.30B · net income $261.6M · FCF $501.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.30B | $1.30B | $1.26B | $1.11B | $986.3M |
| Net Income | $261.6M | $261.6M | $393.3M | $251.0M | $295.3M |
| EBITDA | $482.1M | $482.1M | $634.4M | $431.3M | $442.0M |
| EPS | — | — | 8.80 | 5.62 | 6.61 |
| Gross Margin | 34.6% | 34.6% | 38.7% | 36.7% | 37.3% |
| Operating Margin | 24.6% | 24.6% | 27.9% | 25.3% | 24.2% |
| Net Margin | 20.1% | 20.1% | 31.3% | 22.5% | 29.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.04 | 0.17 | 0.19 |
| Current Ratio | 3.41 | 3.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $501.2M | $501.2M | $408.9M | $-175.1M | $-38.6M |
| Returns | |||||
| ROE | 10.1% | 10.1% | 15.4% | 10.8% | 13.4% |
| Valuation | |||||
| P/E | 12.26 | 12.26 | 10.64 | 15.20 | 12.44 |
| EV/EBITDA | 4.93 | 4.93 | 5.74 | 8.24 | 7.36 |
| P/B | 1.23 | 1.23 | 1.63 | 1.65 | 1.67 |
| Growth & Yield | |||||
| Revenue Growth | 3.4% | 3.4% | 12.8% | 13.0% | — |
| EPS Growth | — | — | 56.6% | -15.0% | — |
| Dividend Yield | 7.4% | 7.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.1%
Start / end P/E
n/dx → n/dx
EPS bridge
8.80 → n/d
Residual
-19.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.